DOCSLIB.ORG

IFT140 with Non-Syndromic Retinal Dystrophy Or CRX with Macular Dystrophy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IFT140 with Non-Syndromic Retinal Dystrophy Or CRX with Macular Dystrophy Investigation of the genetic cause and related phenotypes of rare early onset retinal dystrophies Sarah Hull Institute of Ophthalmology, University College London Submitted to the University College London for the degree of Doctor of Philosophy Supervisors: Prof Andrew R Webster Prof Anthony T Moore March 2016 1 Declaration I, Sarah Hull, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis 2 Abstract Early onset retinal dystrophies (EORD) are a group of disorders presenting in childhood with degenerative abnormalities in photoreceptor cells. They are one of the leading causes of sight impairment in the United Kingdom. Since the initial discovery of Rho causing dominant retinitis pigmentosa in 1990, more than 160 genes have been associated with retinal dystrophy. Many, including CRB1, CRX, and RPE65 exhibit phenotypic heterogeneity and have been associated with more than one retinal disorder. Increasingly, with the advent of next generation sequencing, the association of non-syndromic retinal dystrophy with mutations in syndromic genes has been reported including CEP290, CLN3, and BBS1. In this thesis, a large cohort of patients with EORD underwent both detailed phenotyping to characterise their condition and molecular genetic investigations to identify and investigate the underlying causative variants. Many areas of the presented research were driven by novel findings on whole-exome sequencing such as the association of IFT140 with non-syndromic retinal dystrophy or CRX with macular dystrophy. Other areas were driven by unusual groups of patients with limited published data on their condition such as COL18A1 and Knobloch syndrome, with novel phenotypic features of cone-rod dysfunction and pigmentary glaucoma. Sanger sequencing was performed for confirmation and segregation of identified variants but in addition, for investigation of phenotypically similar patient panels for unusual gene associations. This included systemically mild Hermansky-Pudlak syndrome due to HPS6, juvenile macular dystrophy and CDH3, macular dystrophy and CRX and microcephaly with familial exudative vitreoretinopathy due to LRP5. Functional investigation of missense variants in IFT140 related retinal dystrophy was performed with transient cell transfection. This thesis highlights the vast heterogeneity of rare forms of EORD, presents novel clinical and molecular data and describes the key features of conditions to aid diagnosis and opportunities for future research. 3 Acknowledgments I have been very fortunate to study within such a supportive, motivated and dynamic department. I am most grateful to my supervisors, Prof Tony Moore and Prof Andrew Webster, whose experience, expertise and enthusiasm have taught me so much. Within the laboratory, Dr Gavin Arno has been a great teacher of all molecular techniques and a great collaborator on papers. I am very grateful to Dr Nick Owen for his instruction and advice on cell studies. I would also like to thank Samantha Malka, research coordinator in the department for her essential administrative assistance and support as well as the genetic counsellor team. I am grateful for the invaluable help and advice from many different experts in particular Prof Graham Holder and Dr Anthony Robson in the electrophysiology department as well as Prof Mike Cheetham and Prof Mike Michaelides. This research would not be possible without the generous support of funding bodies specifically the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital, Special Trustees of Moorfields Eye Hospital, and the Foundation Fighting Blindness, USA. To my incredible husband and family, thank you for your constant support and encouragement. Finally, it has been a privilege to be able to investigate and care for a large number of families affected by early onset retinal dystrophies; their willingness to help with research and their optimism despite such challenges is an inspiration. 4 Table of contents DECLARATION............................................................................................................ 2 ABSTRACT .................................................................................................................. 3 ACKNOWLEDGMENTS ............................................................................................... 4 TABLE OF CONTENTS ............................................................................................... 5 LIST OF FIGURES ....................................................................................................... 8 LIST OF TABLES ......................................................................................................... 8 ABBREVIATIONS ...................................................................................................... 10 1 INTRODUCTION ................................................................................................ 11 1.1 The neurosensory retina ........................................................................... 12 1.1.1 Retinal development ................................................................................ 14 1.1.2 Phototransduction and the visual cycle .................................................... 14 1.2 Clinical assessment .................................................................................. 16 1.2.1 Visual function ......................................................................................... 16 1.2.2 Ophthalmoscopy and retinal imaging ....................................................... 18 1.3 Molecular genetics .................................................................................... 19 1.3.1 Mendelian inheritance ............................................................................. 20 1.4 Types of retinal dystrophy ........................................................................ 22 1.4.1 Leber congenital amaurosis ..................................................................... 22 1.4.2 Rod cone dystrophy ................................................................................. 25 1.4.3 Cone rod dystrophy ................................................................................. 26 1.4.4 Macular dystrophy ................................................................................... 26 1.4.5 Abnormal retinal vasculogenesis ............................................................. 26 1.4.6 Syndromic retinal dystrophies .................................................................. 27 1.5 Thesis aims ................................................................................................ 27 2 METHODS .......................................................................................................... 28 2.1 Clinical methods ........................................................................................ 28 2.1.1 History and examination .......................................................................... 28 2.1.2 Retinal imaging ........................................................................................ 29 2.1.3 Electrophysiology .................................................................................... 32 2.2 Molecular genetic methods ...................................................................... 35 2.2.1 DNA isolation and quantification .............................................................. 35 2.2.2 Polymerase chain reaction ...................................................................... 35 2.2.3 Sanger sequencing .................................................................................. 38 2.2.4 Next generation sequencing .................................................................... 39 2.2.4.1 Massively parallel sequencing ...................................................................... 39 2.2.4.2 Variant call alignment and analysis .............................................................. 40 2.2.4.3 Whole genome sequencing .......................................................................... 41 2.2.5 Other molecular investigations................................................................. 41 2.2.6 Variant analysis and functional predictive tools ........................................ 43 2.2.6.1 Determining novelty ...................................................................................... 43 2.2.6.2 Predicting pathogenicity................................................................................ 43 2.2.6.3 Protein modelling .......................................................................................... 44 2.3 Cell studies ................................................................................................ 44 2.3.1.1 Plasmid transformation of cells ..................................................................... 44 2.3.1.2 Culture of single colonies.............................................................................. 45 2.3.1.3 Sequencing of plasmid open reading frame ................................................. 46 2.3.1.4 Site directed mutagenesis ............................................................................ 46 2.3.1.5 Culture of hTERT-RPE1 cells ....................................................................... 49 2.3.1.6 Transient transfection of hTERT-RPE1 cells ................................................ 50 2.4 Zebrafish studies ......................................................................................
Load more

Recommended publications
  • Supplementary Materials: Evaluation of Cytotoxicity and Α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids
    Supplementary Materials: Evaluation of cytotoxicity and α-glucosidase inhibitory activity of amide and polyamino-derivatives of lupane triterpenoids Oxana B. Kazakova1*, Gul'nara V. Giniyatullina1, Akhat G. Mustafin1, Denis A. Babkov2, Elena V. Sokolova2, Alexander A. Spasov2* 1Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences, 71, pr. Oktyabrya, 450054 Ufa, Russian Federation 2Scientific Center for Innovative Drugs, Volgograd State Medical University, Novorossiyskaya st. 39, Volgograd 400087, Russian Federation Correspondence Prof. Dr. Oxana B. Kazakova Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences 71 Prospeсt Oktyabrya Ufa, 450054 Russian Federation E-mail: [email protected] Prof. Dr. Alexander A. Spasov Scientific Center for Innovative Drugs of the Volgograd State Medical University 39 Novorossiyskaya st. Volgograd, 400087 Russian Federation E-mail: [email protected] Figure S1. 1H and 13C of compound 2. H NH N H O H O H 2 2 Figure S2. 1H and 13C of compound 4. NH2 O H O H CH3 O O H H3C O H 4 3 Figure S3. Anticancer screening data of compound 2 at single dose assay 4 Figure S4. Anticancer screening data of compound 7 at single dose assay 5 Figure S5. Anticancer screening data of compound 8 at single dose assay 6 Figure S6. Anticancer screening data of compound 9 at single dose assay 7 Figure S7. Anticancer screening data of compound 12 at single dose assay 8 Figure S8. Anticancer screening data of compound 13 at single dose assay 9 Figure S9. Anticancer screening data of compound 14 at single dose assay 10 Figure S10.
    [Show full text]
  • Analysis of Trans Esnps Infers Regulatory Network Architecture
    Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Anat Kreimer All rights reserved ABSTRACT Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer eSNPs are genetic variants associated with transcript expression levels. The characteristics of such variants highlight their importance and present a unique opportunity for studying gene regulation. eSNPs affect most genes and their cell type specificity can shed light on different processes that are activated in each cell. They can identify functional variants by connecting SNPs that are implicated in disease to a molecular mechanism. Examining eSNPs that are associated with distal genes can provide insights regarding the inference of regulatory networks but also presents challenges due to the high statistical burden of multiple testing. Such association studies allow: simultaneous investigation of many gene expression phenotypes without assuming any prior knowledge and identification of unknown regulators of gene expression while uncovering directionality. This thesis will focus on such distal eSNPs to map regulatory interactions between different loci and expose the architecture of the regulatory network defined by such interactions. We develop novel computational approaches and apply them to genetics-genomics data in human. We go beyond pairwise interactions to define network motifs, including regulatory modules and bi-fan structures, showing them to be prevalent in real data and exposing distinct attributes of such arrangements. We project eSNP associations onto a protein-protein interaction network to expose topological properties of eSNPs and their targets and highlight different modes of distal regulation.
    [Show full text]
  • PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Tuesday, November 6 41
    American Society of Human Genetics 62nd Annual Meeting November 6–10, 2012 San Francisco, California PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Tuesday, November 6 41. Genes Underlying Neurological Disease Room 134 #196–#204 2. 4:30–6:30pm: Plenary Abstract 42. Cancer Genetics III: Common Presentations Hall D #1–#6 Variants Ballroom 104 #205–#213 43. Genetics of Craniofacial and Wednesday, November 7 Musculoskeletal Disorders Room 124 #214–#222 10:30am–12:45 pm: Concurrent Platform Session A (11–19): 44. Tools for Phenotype Analysis Room 132 #223–#231 11. Genetics of Autism Spectrum 45. Therapy of Genetic Disorders Room 130 #232–#240 Disorders Hall D #7–#15 46. Pharmacogenetics: From Discovery 12. New Methods for Big Data Ballroom 103 #16–#24 to Implementation Room 123 #241–#249 13. Cancer Genetics I: Rare Variants Room 135 #25–#33 14. Quantitation and Measurement of Friday, November 9 Regulatory Oversight by the Cell Room 134 #34–#42 8:00am–10:15am: Concurrent Platform Session D (47–55): 15. New Loci for Obesity, Diabetes, and 47. Structural and Regulatory Genomic Related Traits Ballroom 104 #43–#51 Variation Hall D #250–#258 16. Neuromuscular Disease and 48. Neuropsychiatric Disorders Ballroom 103 #259–#267 Deafness Room 124 #52–#60 49. Common Variants, Rare Variants, 17. Chromosomes and Disease Room 132 #61–#69 and Everything in-Between Room 135 #268–#276 18. Prenatal and Perinatal Genetics Room 130 #70–#78 50. Population Genetics Genome-Wide Room 134 #277–#285 19. Vascular and Congenital Heart 51. Endless Forms Most Beautiful: Disease Room 123 #79–#87 Variant Discovery in Genomic Data Ballroom 104 #286–#294 52.
    [Show full text]
  • Synergistic Genetic Interactions Between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models
    BASIC RESEARCH www.jasn.org Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models Rory J. Olson,1 Katharina Hopp ,2 Harrison Wells,3 Jessica M. Smith,3 Jessica Furtado,1,4 Megan M. Constans,3 Diana L. Escobar,3 Aron M. Geurts,5 Vicente E. Torres,3 and Peter C. Harris 1,3 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD) are genetically distinct, with ADPKD usually caused by the genes PKD1 or PKD2 (encoding polycystin-1 and polycystin-2, respectively) and ARPKD caused by PKHD1 (encoding fibrocys- tin/polyductin [FPC]). Primary cilia have been considered central to PKD pathogenesis due to protein localization and common cystic phenotypes in syndromic ciliopathies, but their relevance is questioned in the simple PKDs. ARPKD’s mild phenotype in murine models versus in humans has hampered investi- gating its pathogenesis. Methods To study the interaction between Pkhd1 and Pkd1, including dosage effects on the phenotype, we generated digenic mouse and rat models and characterized and compared digenic, monogenic, and wild-type phenotypes. Results The genetic interaction was synergistic in both species, with digenic animals exhibiting pheno- types of rapidly progressive PKD and early lethality resembling classic ARPKD. Genetic interaction be- tween Pkhd1 and Pkd1 depended on dosage in the digenic murine models, with no significant enhancement of the monogenic phenotype until a threshold of reduced expression at the second locus was breached.
    [Show full text]
  • Whole Exome Sequencing Gene Package Vision Disorders, Version 6.1, 31-1-2020
    Whole Exome Sequencing Gene package Vision disorders, version 6.1, 31-1-2020 Technical information DNA was enriched using Agilent SureSelect DNA + SureSelect OneSeq 300kb CNV Backbone + Human All Exon V7 capture and paired-end sequenced on the Illumina platform (outsourced). The aim is to obtain 10 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate and non-unique reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA-MEM algorithm (reference: http://bio-bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x ABCA4 Cone-rod dystrophy 3, 604116 601691 94 100 100 97 Fundus flavimaculatus, 248200 {Macular degeneration, age-related, 2}, 153800 Retinal dystrophy, early-onset severe, 248200 Retinitis pigmentosa 19, 601718 Stargardt disease
    [Show full text]
  • Evaluation of Variability in Human Kidney Organoids
    ARTICLES https://doi.org/10.1038/s41592-018-0253-2 Evaluation of variability in human kidney organoids Belinda Phipson 1, Pei X. Er1, Alexander N. Combes1,2, Thomas A. Forbes1,3,4, Sara E. Howden1,2, Luke Zappia1,5, Hsan-Jan Yen1, Kynan T. Lawlor1, Lorna J. Hale1,4, Jane Sun6, Ernst Wolvetang6, Minoru Takasato1,7, Alicia Oshlack1,5 and Melissa H. Little 1,2,4* The utility of human pluripotent stem cell–derived kidney organoids relies implicitly on the robustness and transferability of the protocol. Here we analyze the sources of transcriptional variation in a specific kidney organoid protocol. Although individ- ual organoids within a differentiation batch showed strong transcriptional correlation, we noted significant variation between experimental batches, particularly in genes associated with temporal maturation. Single-cell profiling revealed shifts in neph- ron patterning and proportions of component cells. Distinct induced pluripotent stem cell clones showed congruent transcrip- tional programs, with interexperimental and interclonal variation also strongly associated with nephron patterning. Epithelial cells isolated from organoids aligned with total organoids at the same day of differentiation, again implicating relative matura- tion as a confounder. This understanding of experimental variation facilitated an optimized analysis of organoid-based disease modeling, thereby increasing the utility of kidney organoids for personalized medicine and functional genomics. he ability to derive induced pluripotent stem cells (iPSCs) In this study, we provide a comprehensive transcriptional from the somatic cells of patients1, together with directed dif- and morphological evaluation of our kidney organoid protocol. Tferentiation protocols, provides a capacity to model the cell Applying RNA sequencing (RNA-seq) to 57 whole organoids and types affected by disease.
    [Show full text]
  • Ophthalmology
    Ophthalmology Information for health professionals MEDICAL GENETIC TESTING FOR OPHTHALMOLOGY Recent technologies, in particularly Next Generation Sequencing (NGS), allows fast, accurate and valuable diagnostic tests. For Ophthalmology, CGC Genetics has an extensive list of medical genetic tests with clinical integration of results by our Medical Geneticists. 1. EXOME SEQUENCING: Exome Sequencing is a very efficient strategy to study most exons of a patient’s genome, unraveling mutations associated with specific disorders or phenotypes. With this diagnostic strategy, patients can be studied with a significantly reduced turnaround time and cost. CGC Genetics has available 2 options for Exome Sequencing: • Whole Exome Sequencing (WES), which analyzes the entire exome (about 20 000 genes); • Disease Exome by CGC Genetics, which analyzes about 6 000 clinically-relevant genes. Any of these can be performed in the index case or in a Trio. 2. NGS PANELS For NGS panels, several genes associated with the same phenotype are simultaneously sequenced. These panels provide increased diagnostic capability with a significantly reduced turnaround time and cost. CGC Genetics has several NGS panels for Ophthalmology that are constantly updated (www.cgcgenetics.com). Any gene studied in exome or NGS panel can also be individually sequenced and analyzed for deletion/duplication events. 3. EXPERTISE IN MEDICAL GENETICS CGC Genetics has Medical Geneticists specialized in genetic counseling for ophthalmological diseases who may advice in choosing the most appropriate
    [Show full text]
  • Cellular Ciliary Phenotyping Indicates Pathogenicity of Novel Variants in IFT140 and Confrms a Mainzer–Saldino Syndrome Diagnosis Machteld M
    Oud et al. Cilia (2018) 7:1 https://doi.org/10.1186/s13630-018-0055-2 Cilia SHORT REPORT Open Access Cellular ciliary phenotyping indicates pathogenicity of novel variants in IFT140 and confrms a Mainzer–Saldino syndrome diagnosis Machteld M. Oud1,2* , Brooke L. Latour1,2‡, Zeineb Bakey1,2‡, Stef J. Letteboer1,2, Dorien Lugtenberg1, Ka Man Wu1,2, Elisabeth A. M. Cornelissen3, Helger G. Yntema1,4, Miriam Schmidts1,2,5, Ronald Roepman1,2† and Ernie M. H. F. Bongers1† Abstract Background: Mainzer–Saldino syndrome (MZSDS) is a skeletal ciliopathy and part of the short-rib thoracic dysplasia (SRTD) group of ciliary disorders. The main characteristics of MZSDS are short limbs, mild narrow thorax, blindness, and renal failure. Thus far, variants in two genes are associated with MZSDS: IFT140, and IFT172. In this study, we describe a 1-year-old girl presenting with mild skeletal abnormalities, Leber congenital amaurosis, and bilateral hear- ing difculties. For establishing an accurate diagnosis, we combined clinical, molecular, and functional analyses. Methods: We performed diagnostic whole-exome sequencing (WES) analysis to determine the genetic cause of the disease and analyzed two gene panels, containing all currently known genes in vision disorders, and in hearing impairment. Upon detection of the likely causative variants, ciliary phenotyping was performed in patient urine- derived renal epithelial cells (URECs) and rescue experiments were performed in CRISPR/Cas9-derived Ift140 knock out cells to determine the pathogenicity of the detected variants in vitro. Cilium morphology, cilium length, and intrafa- gellar transport (IFT) were evaluated by immunocytochemistry. Results: Diagnostic WES revealed two novel compound heterozygous variants in IFT140, encoding IFT140.
    [Show full text]
  • ZNF408 Polyclonal Antibody
    PRODUCT DATA SHEET Bioworld Technology,Inc. ZNF408 polyclonal antibody Catalog: BS71268 Host: Rabbit Reactivity: Human,Mouse,Rat BackGround: by affinity-chromatography using epitope-specific im- Zinc-finger proteins contain DNA-binding domains and munogen and the purity is > 95% (by SDS-PAGE). have a wide variety of functions, most of which encom- Applications: pass some form of transcriptional activation or repression. WB 1:500 - 1:2000 The majority of zinc-finger proteins contain a Krüp- IHC 1:50 - 1:200 pel-type DNA binding domain and a KRAB domain, Storage&Stability: which is thought to interact with KAP1, thereby recruit- Store at 4°C short term. Aliquot and store at -20°C long ing histone modifying proteins. As a member of the term. Avoid freeze-thaw cycles. Krüppel C2H2-type zinc-finger protein family, ZNF396 Specificity: (zinc finger protein 396), also known as PRDM17 (PR ZNF408 polyclonal antibody detects endogenous levels domain zinc finger protein 17), is a 720 amino acid nu- of ZNF408 protein. clear protein that contains 10 C2H2-type zinc fingers. The DATA: gene encoding ZNF408 maps to human chromosome 11, which houses over 1,400 genes and comprises nearly 4% of the human genome. Jervell and Lange-Nielsen syn- drome, Jacobsen syndrome, Niemann-Pick disease, he- reditary angioedema and Smith-Lemli-Opitz syndrome are associated with defects in genes that maps to chro- mosome 11. Product: Western blot analysis of extracts of various cells, using ZNF408 anti- Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, body. 50% glycerol, pH7.2 Note: Molecular Weight: For research use only, not for use in diagnostic procedure.
    [Show full text]
  • Basement Membranes in Diseases Affecting the Eye, Kidney
    Van Agtmael, T. and Bruckner-Tuderman, L. (2010) Basement membranes and human disease. Cell and Tissue Research, 339 (1). pp. 167-188. ISSN 0302-766X http://eprints.gla.ac.uk/35275/ Deposited on: 30 August 2010 Enlighten – Research publications by members of the University of Glasgow http://eprints.gla.ac.uk Basement membranes and human disease Tom van Agtmael§ and Leena Bruckner-Tuderman* § Faculty of Biomedical and Life Sciences, University of Glasgow, Glasgow, U.K. and * Dept. of Dermatology, University Medical Center Freiburg and Freiburg Institute for Advanced Studies, Freiburg, Germany Corresponding authors: Tom Van Agtmael Faculty of Biomedical and Life Sciences, Davidson Building, University of Glasgow, University Avenue, Glasgow UK, [email protected],. Leena Bruckner-Tuderman Department of Dermatology, University Medical Center Freiburg, Hauptstr. 7, 79104 Freiburg, Germany. E-mail: [email protected] Keywords: basement membrane, laminin, collagen, laminin, nidogen Abbreviations BM: basement membrane, NMJ neuromuscular junction, DEJ dermo epidermal junction, SJS Schwartz Jampel syndrome, DDSH Dyssegmental dysplasia silverman handmaker type, EB epidermolysis bullosa, GBM glomerular basement membrane 1 Abstract In 1990 the role of basement membranes in human disease was established by the identification of COL4A5 mutations in Alport’s syndrome. Since then the number of diseases caused by mutations in basement membrane components has steadily increased as has our understanding of the roles of basement membranes in organ development and function. However, many questions remain as to the molecular and cellular consequences of these mutations and how they lead to the observed disease phenotypes. Despite this, exciting progress has recently been made with potential treatment options for some of these so far incurable diseases.
    [Show full text]
  • Functional Characterization of the Human RPGR Proximal Promoter
    Biochemistry and Molecular Biology Functional Characterization of the Human RPGR Proximal Promoter Xinhua Shu,*,1,2 Julie R. Simpson,2 Alan W. Hart,2 Zhihong Zeng,3 Sarita Rani Patnaik,1 Philippe Gautier,2 Emma Murdoch,2 Brian Tulloch,2 and Alan F. Wright*,2 PURPOSE. Mutations in the retinitis pigmentosa (RP) GTPase promoter will facilitate understanding of the functional role regulator (RPGR) gene account for more than 70% of X-linked of RPGR in the retina and gene therapy of X-linked RP. (Invest RP cases. This study aims to characterize the proximal Ophthalmol Vis Sci. 2012;53:3951–3958) DOI:10.1167/ promoter region of the human RPGR gene. iovs.11-8811 0 METHODS. The 5 -flanking region (5 kb) of human RPGR was cloned and sequenced. A potential transcription start site and etinitis pigmentosa (RP) is a genetically heterogeneous transcription factor binding motifs were identified by bio- Rgroup of retinal degenerations that affect 1 in 4000 in the informatic analysis. Constructs containing the putative human general population.1,2 Most cases are inherited in an autosomal RPGR promoter region upstream of a luciferase reporter gene dominant, autosomal recessive, X-linked, or mitochondrial were generated and analyzed by transient transfection and manner, but oligogenic inheritance has been established in a luciferase assays. Transgenic mouse lines carrying a 3-kb small proportion of families.3 X-linked RP (XLRP) is one of the human RPGR promoter sequence fused to lacZ were generated most consistently severe forms of RP, with a reported average and RPGR proximal promoter activity was analyzed by X-gal age at onset of 7.2 6 1.7 years.4 XLRP affects 10% to 20% of all staining.
    [Show full text]
  • And Cone-Rod Dystrophy in Dogs
    University of Pennsylvania ScholarlyCommons Departmental Papers (Vet) School of Veterinary Medicine 2012 RPGRIP1 and Cone-Rod Dystrophy in Dogs Tatyana N. Kuznetsova Barbara Zangerl University of Pennsylvania, [email protected] Gustavo D. Aguirre University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/vet_papers Part of the Eye Diseases Commons, Geriatrics Commons, Medical Biotechnology Commons, Medical Genetics Commons, Medical Immunology Commons, Ophthalmology Commons, and the Veterinary Medicine Commons Recommended Citation Kuznetsova, T. N., Zangerl, B., & Aguirre, G. D. (2012). RPGRIP1 and Cone-Rod Dystrophy in Dogs. Retinal Degenerative Diseases: Advances in Experimental Medicine and Biology, 723 321-328. http://dx.doi.org/ 10.1007/978-1-4614-0631-0_42 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/vet_papers/85 For more information, please contact [email protected]. RPGRIP1 and Cone-Rod Dystrophy in Dogs Abstract Cone–rod dystrophies (crd) represent a group of progressive inherited blinding diseases characterized by primary dysfunction and loss of cone photoreceptors accompanying or preceding rod death. Recessive crd type 1 was described in dogs associated with an RPGRIP1 exon 2 mutation, but with lack of complete concordance between genotype and phenotype. This review highlights role of the RPGRIP1, a component of complex protein networks, and its function in the primary cilium, and discusses the potential mechanisms of genotype–phenotype discordance observed in dogs with the RPGRIP1 mutation. Keywords RPGRIP1, polymorphism, cone-rod dystrophy, protein network, photoreceptor cilia Disciplines Eye Diseases | Geriatrics | Medical Biotechnology | Medical Genetics | Medical Immunology | Ophthalmology | Veterinary Medicine This journal article is available at ScholarlyCommons: https://repository.upenn.edu/vet_papers/85 Published in final edited form as: Adv Exp Med Biol.
    [Show full text]